Newly Awarded Grants

United States Department of Defense (DOD)- Incoming Subaward

Title: Treat Implant loosening of Percutaneous Osseointegrated Prosthetic Limbs with Intermittent Parathyroid Hormone
Principal Investigator: Matthew Greenblatt, MD PhD
Period of Support: 09/01/2021-08/31/2024
Total Direct Costs: $54,117

The Pershing Square Sohn Cancer Research Alliance

Title: Evolution and antigenicity of complex amplicons
Principal Investigator: Marcin Imielinski, MD PhD
Period of Support: 07/01/2021-06/30/2024
Total Direct Costs: $545,454

National Institutes of Health (R37)

Title: Cell-of-Origin Footprints of Passenger Mutations in Human Lung Cancer
Principal Investigator: Marcin Imielinski, MD PhD
Period of Support:09/23/2021-08/31/2026
Total Direct Costs: $1,718,599

Breast Cancer Research Foundation

Title: Isolation and Characterization of Metastatic Breast Cancer Cell-of-Origin
Principal Investigator: Tan Ince, MD PhD
Period of Support:10/01/2021-09/30/2022
Total Direct Costs: $158,333

National Institutes of Health (RM1)- Incoming Subaward

Title: Structure, Function, and Dynamics of Large Molecular Complexes that Execute and Regulate Genome Function
Principal Investigator: Steven Josefowicz, PhD
Period of Support: 04/01/2021- 03/31/2022
Total Direct Costs: $170,022

National Institutes of Health (SBIR) -Incoming Subaward

Title: Leveraging functional genomics to create an epigenetic toolbox for inflammation research and drug discovery
Principal Investigator: Steven Josefowicz, PhD
Period of Support: 05/01/2021-05/04/2022
Total Direct Costs: $92,091

National Science Foundation

Title: Collaborative Research: SCH: Integrated Analysis of Single-Cell and Spatially Resolved Omics Data
Principal Investigator: Luigi Marchionni, MD PhD
Period of Support: 09/01/2021- 08/31/2025
Total Direct Costs: $147,436

National Institutes of Health (R01)

Title: Interferon regulation by NBR1-driven chaperone-mediated autophagy in stellate cells in liver cancer
Principal Investigator: Jorge Moscat, PhD
Period of Support: 12/01/2021- 11/30/2026
Total Direct Costs: $1,188,336

United States Department of Defense (DOD)

Title: Novel Complex Structural Variants And Epigenetic Alterations Link The Genomes Of Prostate Cancer In African Americans With Outcome Disparity.
Principal Investigator: Juan Miguel Mosquera, MD
Period of Support: 08/15/2021- 08/14/2023
Total Direct Costs: $741,658

STARR Cancer Consortium

Title: Defining the evolution and tumor microenvironment interactions of classic Hodgkin lymphoma through single-cell multi-omics and genetically engineered mouse models
Principal Investigator: Seung Ha (Anna) Nam, MD (Co-PI)
Period of Support: 01/01/2022-12/31/2023
Total Direct Costs: $364,000

STARR Cancer Consortium

Title: Early intervention for the prevention of blood cancer development
Principal Investigator: Seung Ha (Anna) Nam, MD (Co-PI)
Period of Support: 01/01/2022-12/31/2023
Total Direct Costs: $191,000
 

Weill Cornell Medicine Internal Grants

JumpStart Program

Title: Targeting Drivers of tumor heterogeneity to block neuroendocrine prostate cancer progression
Principal Investigator: Nicholas Brady, PhD
Period of Support:07/01/2021-06/30/2024
Total Direct Costs: $300,000

WCM SPORE in Prostate Cancer Career Enhancement Program

Title: Targeting drivers of tumor heterogeneity to block the progression to NEPC
Principal Investigator: Nicholas Brady, PhD
Period of Support: 09/01/2021- 08/31/2022
Total Direct Costs: $50,000

WCM Prostate Cancer SPORE Developmental Research Program

Title:  A versatile patient derived prostate cell culture system
Principal Investigator: Tan Ince, MD PhD
Period of Support: 08/01/2021- 07/31/2022
Total Direct Costs: $75,000

WCM Prostate Cancer SPORE Developmental Research Program

Title: Therapeutic targeting the neuroendocrine prostate cancer stroma
Principal Investigator: Jorge Moscat, PhD and Maria Diaz-Meco, PhD
Period of Support: 09/01/2021- 08/31/2022
Total Direct Costs: $75,000

Clinical & Translational Science Center (CTSC)

Title: Small. Molecule inhibitors of G3BP1 reinvigorate SPOP tumor suppressor
Principal Investigator: Pengbo Zhou, PhD
Period of Support: 07/01/2021-06/30/2022
Total Direct Costs: $50,000
 

Industry Sponsored Research Agreements 

Predictive Oncology, Inc.

Title: SRA: TumorGenesis, Inc – Ovarian cancer cell based panning project
Principal Investigator: Tan Ince, MD PhD
Period of Support: 08/11/2021-08/10/2022
Total Direct Costs: 94,880

Novartis Pharmaceuticals Corp.

Title:  Evaluation of eltrombopag interference in total bilirubin, direct bilirubin and creatinine clinical chemistry tests
Principal Investigator: Zhen Zhao, PhD
Period of Support: 10/26/2021-10/25/2022
Total Direct Costs: $74,000
 

Fellowships

American Association for Cancer Research

Title: Role of the linker histones H1 In lymphomas
Principal Investigator: Antonin Papin, PhD (postdoc in Cesarman Lab)
Period of Support: 07/01/2021- 06/30/2023
Total Direct Costs: $120,000

Fondazione AIRC per la ricerca sul cancro

Title: Deciphering the role of androgen receptor in spatially resolved mesenchymal populations in prostate cancer
Principal Investigator: Filippo Pederzoli, PhD (postdoc in Loda Lab)
Period of Support: 01/01/2022- 12/31/2023
Total Direct Costs: $142,198

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700